View Older Stories

Mar 25, 2026 06:11AM RBC Capital: 'Takeout Analysis Suggests BCRX Shares Still Undervalued'

Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'

Mar 16, 2026 10:52AM BioCryst Pharma (BCRX) shares quickly gain

Feb 26, 2026 01:30PM TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)

Feb 26, 2026 07:58AM BioCryst Pharma (BCRX) Tops Q4 EPS by 108c; offers outlook

Feb 18, 2026 08:18AM Evercore ISI Resumes BioCryst Pharma (BCRX) at Outperform, Adds to Core SMID list

Jan 13, 2026 07:13AM BioCryst Pharma (BCRX) Reiterated at Overweight by Cantor Fitzgerald

Jan 13, 2026 04:05AM BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens: A Strong Quarter

Jan 12, 2026 07:04AM BioCryst reports 2025 ORLADEYO revenue of $601 million, up 37%

Jan 9, 2026 07:16AM BioCryst raises ORLADEYO drug price by 9% starting January 2026

Dec 16, 2025 06:54AM BioCryst Pharma (BCRX) PT Raised to $32 at H.C. Wainwright

Dec 15, 2025 04:03AM BioCryst Pharma's (BCRX) Orladeyo Pediatric Approval Will Drive Sales - Citizens

Dec 12, 2025 10:16AM TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)

Dec 3, 2025 07:01AM BioCryst receives antitrust clearance for Astria acquisition

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 6, 2025 08:00AM BioCryst presents pediatric HAE data at medical conference

Nov 5, 2025 04:53AM BioCryst Pharma (BCRX) PT Lowered to $25 at Citizens After Missing 3Q Sales Consensus

Nov 4, 2025 09:12AM Cantor Fitzgerald Reiterates Overweight Rating on BioCryst Pharma (BCRX)

Nov 3, 2025 07:03AM BioCryst Pharma (BCRX) Tops Q3 EPS by 11c ; Offers Guidance

Oct 15, 2025 07:24AM H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)

Oct 15, 2025 07:07AM BioCryst Pharma (BCRX) PT Raised to $26 at Cantor Fitzgerald After Astria (ATXS) Acquisition

Oct 15, 2025 04:39AM TD Cowen Resumes BioCryst Pharma (BCRX) at Buy, PT $30

Oct 15, 2025 04:23AM BioCryst Pharma (BCRX) PT Raised to $27 at Citizens on Navenibart Deal, Strong HAE Fit

Oct 14, 2025 04:34PM Oppenheimer Downgrades Astria Therapeutics (ATXS) to Perform

Oct 14, 2025 03:47PM BioCryst Pharma (BCRX) PT Raised to $15 at RBC Capital Amid 10pct Decline

Oct 14, 2025 03:04PM BioCryst Pharma (BCRX) PT Raised to $15 at Jefferies

Oct 14, 2025 06:55AM BioCryst Pharma (BCRX) Halted, News Pending

Oct 1, 2025 06:36AM Evercore ISI Downgrades BioCryst Pharma (BCRX) to In Line

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Aug 11, 2025 07:02AM BioCryst chief research officer to depart September 1

Aug 4, 2025 07:01AM BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance

Jul 24, 2025 12:20PM RBC Capital on BioCryst Pharma (BCRX): 'We See Shares Undervalued'

Jul 7, 2025 07:01AM BioCryst (BCRX) names Babar Ghias as CFO and head of corporate development

Jun 27, 2025 07:01AM BioCryst Pharma (BCRX) Announces Sale of European ORLADEYO Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025 07:02AM BioCryst Pharma (BCRX) Presents New Data on the Long-term Efficacy and Safety of ORLADEYO

Jun 13, 2025 07:00AM BioCryst Pharma (BCRX): ORLADEYO Approved in Colombia

Jun 6, 2025 07:00AM BioCryst Pharma (BCRX) Achieves Reimbursement for ORLADEYO Across all Major European Countries

May 30, 2025 07:01AM BioCryst Pharma (BCRX) Highlights Real-world Data Showing ORLADEYO Consistently Reduces HAE Attacks Across All Ages

May 16, 2025 07:01AM BioCryst Pharma (BCRX) Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO

May 6, 2025 09:43AM BioCryst Pharma (BCRX) PT Raised to $13 at RBC Capital; 'Strong Out of the Gate in 2025'

May 5, 2025 04:08PM BioCryst Pharma (BCRX) PT Raised to $14 at Jefferies

May 5, 2025 07:02AM BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance

May 1, 2025 07:02AM BioCryst Pharma (BCRX) Appoints Steve Frank to its Board

Apr 29, 2025 06:35AM Cantor Fitzgerald Starts BioCryst Pharma (BCRX) at Overweight

Apr 23, 2025 04:17AM Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)

Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets

Mar 3, 2025 04:34AM Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)

Feb 25, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)

Feb 25, 2025 04:11AM Citizens JMP Reiterates Market Outperform Rating on BioCryst Pharma (BCRX)

Feb 24, 2025 01:18PM Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)

View Older Stories